Oxford-based technology company Arctoris has developed a fully automated drug discovery platform.
Arctoris, which recently celebrated its fifth anniversary, unveiled its new and expanded robotic platform, Ulysses, which through end-to-end automation delivers reliable, reproducible, and fully auditable datasets.
According to the company, the solution enables better decision-making early in the drug discovery process.
Martin-Immanuel Bittner CEO of Arctoris, said: “The drug discovery ecosystem is evolving rapidly, and the key to success is having access to the right data at the right time, to progress the right projects towards the clinic.
“Arctoris plays an important role in enabling true data-driven drug discovery globally, by generating the data that powers decisions in biotech and pharma companies on three continents.”
The company also recently announced partnerships with biotechnology company Insilico Medicine and bioinformatics venture firm Syntekabio.
